The sphingomyelin/ceramide pathway is involved in ERK1/2 phosphorylation, cell proliferation, and uPAR overexpression induced by tissue-type plasminogen activator FRANÇOISE MAUPAS-SCHWALM, NATHALIE AUGÉ, CATHERINE ROBINET, JEAN-PIERRE CAMBUS * , SARAH J. PARSONS † , ROBERT SALVAYRE 1 and ANNE NÈGRE-SALVAYRE 1 Inserm U-466, CHU Rangueil, Toulouse, France; * Laboratoire d'Hematologie, CHU Rangueil, Toulouse, France; and † Microbiology Department and Cancer Center, University of Virginia, Charlottesville, Virginia, USA 1 Correspondence: Biochimie-INSERM U466, IFR-31, CHU Rangueil 1, avenue Jean Poulhès-TSA-50032, 31059 Toulouse Cedex 9, France. E-mail: anesalv@rangueil.inserm.fr or salvayre@rangueil.inserm.fr <h3>SPECIFIC AIMS</h3> Plasminogen activators urokinase plasminogen activator (uPA) and tissue-type plasminogen activator (tPA) and their receptor, uPAR, have been implicated in various physiological processes such as clot lysis, extracellular proteolysis, matrix remodeling, and wound healing. This system is also involved in the regulation of cell migration, adhesion, and proliferation, with major implications for cancer dissemination and cardiovascular diseases. So far, the nature and interactions between the different signaling pathways elicited by the plasminogen system are only partly understood. On the other hand, the sphingomyelin/ceramide/sphingosine-1-phosphate (Spm/Cer/S1P) pathway has recently emerged as a major signaling system that regulates cellular responses such as growth, survival, and migration and is implicated in pathophysiology of cancer or
/lp/fed-of-american-socs-for-experimental-biology/the-sphingomyelin-ceramide-pathway-is-involved-in-erk1-2-a1o2F1WGkA